Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Flucloxacillin is now established as an important cause of cholestatic liver disease. Warnings about the risk have not had an impact on prescribing practices in the UK, where it remains the predominantly prescribed antistaphylococcal oral antibiotic. This situation in the UK is in sharp contrast to regulatory actions and changes in prescribing habits in Australia after identification of the risk of cholestasis associated with flucloxacillin,
and to the predominant use of the alternative drug dicloxacillin in the U SA.
I am not aware there has been any publicity about this in the UK and it is a common antibiotic used in my department. Any feedback ?
From the British National Formulary
Quote:
CSM advice (hepatic disorders)
CSM has advised that very rarely cholestatic jaundice and hepatitis may occur up to several weeks after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. CSM has reminded that:
flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin;
flucloxacillin should be used with caution in patients with hepatic impairment;
careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials.
Flulclox went out of favour in Australia about 10 years ago following the initial publication of this Australian research, but has now crept back into fairly common usage, as almost all antibiotics have some sort of hepatic effect and it can be the best drug for a number of lower limb infections for those with out liver disease.
__________________ Stephen Tucker Calvary Health Care
Flulclox went out of favour in Australia about 10 years ago following the initial publication of this Australian research, but has now crept back into fairly common usage, as almost all antibiotics have some sort of hepatic effect and it can be the best drug for a number of lower limb infections for those with out liver disease.
Flucloxacillin & Liver Disease
Linear Mode
